HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, has announced its plans to voluntarily delist from the Nasdaq Capital Market and deregister its common stock under the Securities Exchange Act of 1934. This decision comes in light of the impending Asset Sale to Gilead Sciences, Inc., which involves the transfer of assets related to HOOKIPA's HB-400 and HB-500 programs. Following the Asset Sale, HOOKIPA intends to dissolve and liquidate, subject to stockholder approval at a special meeting scheduled for July 29, 2025. The company cites the economic burden of ongoing reporting requirements as a factor in its decision, as compliance would diminish the assets available for distribution to stockholders. If approved, HOOKIPA plans to file a Certificate of Dissolution with the Delaware Secretary of State, marking the commencement of its winding up and liquidation process.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。